Back to today’s briefing

Story perspectives

Pharma Giants Warn Against Global Price Link: Innovation at Risk

11/8/2025

50 11 Full Breakdown

Summary

Story summary

Pharmaceutical companies argue that linking US drug prices to global standards would threaten innovation and American biomedical leadership.
They contend price restrictions could hinder the development of new medical advances.
Critics point to high industry profits and insulin price disparities.
A study shows Novo Nordisk A/S, the Danish pharmaceutical company, could produce Ozempic for under $5 despite US prices reaching nearly $1,000.

1 of 1

Story summary

Pharmaceutical companies argue that linking US drug prices to global standards would threaten innovation and American biomedical leadership.
They contend price restrictions could hinder the development of new medical advances.
Critics point to high industry profits and insulin price disparities.
A study shows Novo Nordisk A/S, the Danish pharmaceutical company, could produce Ozempic for under $5 despite US prices reaching nearly $1,000.